Skip to main content
Clinical Trials/NCT06298812
NCT06298812
Recruiting
Not Applicable

A Prospective, Single-Arm, Multi-Center, Registry Post-Approval Study of Growth Modulation in the Treatment of Idiopathic Scoliosis With the REFLECT™ Scoliosis Correction System

Globus Medical Inc2 sites in 1 country100 target enrollmentApril 8, 2024

Overview

Phase
Not Applicable
Intervention
REFLECT Scoliosis Correction System
Conditions
Idiopathic Scoliosis
Sponsor
Globus Medical Inc
Enrollment
100
Locations
2
Primary Endpoint
Primary Safety
Status
Recruiting
Last Updated
2 months ago

Overview

Brief Summary

The purpose of this multi-center, prospective, single-arm registry Post-Approval Study (PAS) is to evaluate the radiographic and clinical outcomes of 100 patients with idiopathic scoliosis treated with the REFLECT™ Scoliosis Correction System, as a condition of HDE approval

Detailed Description

The REFLECT™ Scoliosis Correction System is designed for continued growth and mobility of the spine as well as straightening of the spine by holding the segments in a more natural anatomic position using non-rigid materials. REFLECT™ uses a growth modulation technique in which growth of the patient is used to achieve progressive scoliosis correction. The REFLECT™ Scoliosis Correction System is indicated for skeletally immature patients who require surgical treatment to obtain and maintain correction of progressive idiopathic scoliosis, who have a major Cobb angle of 30 to 65 degrees whose osseous structure is dimensionally adequate to accommodate screw fixation, as determined by radiographic imaging. Patients should have failed bracing and/or are intolerant to brace wear. A total of 100 patients will be prospectively enrolled and treated at a minimum of 5 U.S. sites, with a maximum of 20 subjects at any one site, with sequential enrollment from each site. Patients will be followed for 5 years with evaluations at the following timepoints: preoperative, intraoperative, immediate postoperative (first erect), 6 weeks, 6 months, 12 months, 24 months, and 60 months. Primary and secondary outcomes from 100 patients enrolled and treated with REFLECT™ will be summarized.

Registry
clinicaltrials.gov
Start Date
April 8, 2024
End Date
March 31, 2032
Last Updated
2 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of progressive idiopathic scoliosis
  • Preoperative major Cobb angle 30°-65°
  • Preoperative flexibility to ≤30° on side bending radiograph (left or right)
  • Skeletally immature at the time of surgery with Risser sign \<5 or Sanders score \<8
  • Osseous structure dimensionally adequate to accommodate screw fixation, as determined by radiographic imaging
  • Failed or intolerant to bracing
  • Signed informed consent and/or assent forms specific to this study

Exclusion Criteria

  • Prior spinal surgery at the level(s) to be treated
  • Documented poor bone quality, defined as a T-score of -1.5 or less
  • Presence of any systemic infection, local infection, or skin compromise at the surgical site
  • Any medical or surgical condition which would preclude the potential benefit of spinal surgery, such as coagulation disorders, allergies to the implant materials, and patient's unwillingness or inability to cooperate with post-operative care instructions
  • Unwillingness, inability, or living situation (e.g. custody arrangements, homelessness, detention) that would preclude ability to return to the study site for follow-up visits as described in protocol and Informed Consent
  • Active participation in a drug or device study that is more than minimal risk such that participation would confound the measurements of the present study

Arms & Interventions

REFLECT

Enrolled patients are treated with the REFLECT Scoliosis System. This is an HDE-approved device.

Intervention: REFLECT Scoliosis Correction System

Outcomes

Primary Outcomes

Primary Safety

Time Frame: 60 months postoperative

Serious adverse events (SAEs) and device- or procedure-related adverse events (AEs)

Primary Probable Benefit

Time Frame: 60 months postoperative

Maintenance of major Cobb angle less than or equal to 40°

Secondary Outcomes

  • SRS score(60 months postoperative)
  • Device integrity(60 months postoperative)
  • Failure analysis(60 months postoperative)
  • Curve progression(60 months postoperative)
  • Composite endpoint analysis(60 months postoperative)

Study Sites (2)

Loading locations...

Similar Trials